Geneus Health and PanaceaPGX Partnership Breaks Down Barriers To Better Health Outcomes
SAN ANTONIO (PRWEB) April 16, 2018 -- Famed author Lewis Carroll is widely credited with the phrase, “If you don't know where you're going, any road’ll get you there.” Well, this old adage seems to have taken on a new meaning for people concerned with their healthcare. According to Geneus Health CEO, Justin Jones, “there are a growing number of people who are disenchanted with past ‘healthcare’ experiences that now want specific answers that only their DNA can provide.” To help facilitate their demands, Geneus Health has joined with PanaceaPGX to make their proprietary DNA testing platform available to a wider audience.
Geneus Health is the nation’s leading DNA testing laboratory focused on addiction. The innovative platform is built upon the life’s work of Dr. Kenneth Blum, co-discoverer of the first known addiction gene. After 40 years of research consisting of countless papers and peer reviewed clinical trials published in medical journals, Dr. Blum along with Geneus Health has developed the Genetic Addiction Risk Score (GARS™) test. GARS™ identifies and quantifies key genetic markers associated with addiction.
GARS™ provides the road to be traveled, but it is Dr. Blum and Geneus Health’s restoreGen™ that provides the vehicle to a sustainable recovery. restoreGen™ is a line of 6 genetically directed neuro-nutrients. Each one is uniquely designed and genetically guided by the results of the GARS™ test based on an individual’s genetics. These all-natural neuro-nutrients have been scientifically proven to balance brain chemistry while restoring its function. Supported by more than 35 clinical trials, the restoreGen™ family of neuro-nutrient supplements has also been proven to reduce and even eliminate craving behaviors. This is the first and only genetically directed addiction management platform known amongst addiction professionals as Precision Addiction Management (PAM™).
PanaceaPGX uses its cutting-edge telemedicine technology, which allows certified providers to determine GARSTM relevance to the patient prior to testing, and once tested, review results with patient, enhancing the overall consumer experience.
Geneus Health and Dr. Blum wholeheartedly believe that identification of addiction risk via the GARS™ test combined with restoreGen™ neuro-nutrient supplements to curb addiction cravings will play a critical role in diminishing the opioid epidemic.
To learn more about Genetic Addiction Risk Score (GARS™) and/or the genetically directed restoreGen™ supplements please visit http://www.geneushealth.com and http://www.restoreGen.com or call 844-800-2334.
Joe Ullrich, Omni Publicity, http://www.geneushealth.com, 813-944-2024, [email protected]
Share this article